Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.43 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.43 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3893470 | 1.00 | DPP4 (0.48) | DPP4IP6K1IP6K3IP6K2DPP9 | |
| SCHEMBL3895305 | 0.92 | DPP4 (0.48) | DPP4IP6K1IP6K3IP6K2DPP9 | |
| SCHEMBL3895296 | 0.92 | DPP4 (0.48) | DPP4IP6K1IP6K3IP6K2DPP9 | |
| SCHEMBL3890620 | 0.90 | DPP4 (0.61) | DPP4 | |
| SCHEMBL3890613 | 0.90 | DPP4 (0.61) | DPP4 | |
| SCHEMBL3892554 | 0.89 | DPP4 (0.46) | DPP4IP6K1IP6K3IP6K2AKR1C4 | |
| SCHEMBL3892561 | 0.89 | DPP4 (0.46) | DPP4IP6K1IP6K3IP6K2AKR1C4 | |
| Hydrochloric Acid SCHEMBL3891991 | 0.83 | DPP4 (0.65) | DPP4IP6K1IP6K3IP6K2DPP9 | |
| Hydrochloric Acid SCHEMBL3891996 | 0.83 | DPP4 (0.65) | DPP4IP6K1IP6K3IP6K2DPP9 | |
| SCHEMBL3893478 | 0.79 | DPP4 (0.57) | DPP4DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547710-B2 | Fused heterocyclic compounds as peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1527049-B8 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1527049-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060135530-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1527049-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004014860-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135530-A1 | Fused heterocyclic compounds | NR4A3, DPP3, INSR | DPP4 13/4885IP6K1 4473/4885IP6K3 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.